← Leaderboards
Nancy J Olsen
Vanderbilt University
$6,548,556
Attributed
$10,936,053
Total exposure
15
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2007–22$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$10,936,053 · 15
By mechanism
U01$6,793,002 · 1
P50$1,562,002 · 1
RC1$974,414 · 1
U34$682,773 · 1
R01$399,266 · 2
R21$389,191 · 1
Top collaborators
- David R Karp9 shared
- Thomas J. Kodadek2 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Conrad Wagner$6,130,994
- Nancy Joan Brown$32,445,188
- Barney S Graham$269,836
- Nipun B. Merchant$6,490,068
- Jordan D Berlin$14,361,518
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectRheumatoid ArthritisHuman Therapy EvaluationDrug Screening /EvaluationOrganLupusInsightEarly DiagnosisClinical TrialsPreventSystemic Lupus ErythematosusAutoantibodiesImmunologicsLaboratoriesResearch PersonnelImmunopathology TherapyClinical Trial Phase IDisease ProgressionPre-ClinicalTherapeutic InterventionMorbidity - Disease RatePharmaceutical PreparationsBlood
Grant awards (42)
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE)$934,842
U01 · FY2022 · AR · contact PI
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE)$1,315,081
U01 · FY2021 · AR · contact PI
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE)$1,649,605
U01 · FY2019 · AR · contact PI
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE)$1,449,776
U01 · FY2018 · AR · contact PI
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE)$1,443,698
U01 · FY2017 · AR · contact PI
Hydroxychloroquine Treatment for Prevention of Systemic Lupus Erythematosus$321,048
U34 · FY2016 · AR · contact PI
Targeting RAS Gene Pathways in Psoriatic Arthritis$171,435
R21 · FY2016 · AR · contact PI
Hydroxychloroquine Treatment for Prevention of Systemic Lupus Erythematosus$361,725
U34 · FY2015 · AR · contact PI
Targeting RAS Gene Pathways in Psoriatic Arthritis$217,756
R21 · FY2015 · AR · contact PI
Predictors of Disease Progression in Human Lupus Syndromes$277,925
P50 · FY2011 · AR · contact PI
High Throughput Screening of the Autoimmune Epitome$485,635
RC1 · FY2010 · AR
Predictors of Disease Progression in Human Lupus Syndromes$340,848
P50 · FY2010 · AR · contact PI
High Throughput Screening of the Autoimmune Epitome$488,779
RC1 · FY2009 · AR
Predictors of Disease Progression in Human Lupus Syndromes$302,584
P50 · FY2009 · AR · contact PI
Predictors of Disease Progression in Human Lupus Syndromes$369,657
P50 · FY2008 · AR · contact PI
Predictors of Disease Progression in Human Lupus Syndromes$270,988
P50 · FY2007 · AR · contact PI
Cyclophosphamide and Mycophenolate in Lupus Nephritis$12,104
M01 · FY2004 · RR
Creatine and Magnesium Supplementation in Patients with Dermatomyositis$2,752
M01 · FY2004 · RR
Gene Expression and Diagnosis of Diabetes$119,957
R41 · FY2003 · DK
BMS 188667 &BMS 224818 INTRAVENOUS FOR RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
ANTI-TNF CHIMERIC MONOCLONAL ANTIBODY IN ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
PHASE I EVALUATION OF AG4263 IN RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
TYPE 2 COLLAGEN INDUCTION OF RHEUMATOID ARTHRITIS-- OFF NONSTEROIDAL AGENTS$0
M01 · FY2002 · RR
ANTI-TNF CHIMERIC MONOCLONAL ANTIBODY IN ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
TYPE 2 COLLAGEN INDUCTION OF RHEUMATOID ARTHRITIS-- OFF NONSTEROIDAL AGENTS$0
M01 · FY2001 · RR
TYPE 2 COLLAGEN INDUCTION OF RHEUMATOID ARTHRITIS-- OFF NONSTEROIDAL AGENTS$0
M01 · FY2001 · RR
TYPE 2 COLLAGEN INDUCTION OF RHEUMATOID ARTHRITIS-- OFF NONSTEROIDAL AGENTS$0
M01 · FY2001 · RR
BMS 188667 &BMS 224818 INTRAVENOUS FOR RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
BMS 188667 &BMS 224818 INTRAVENOUS FOR RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
BMS 188667 &BMS 224818 INTRAVENOUS FOR RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
PHASE I EVALUATION OF AG4263 IN RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
PHASE I EVALUATION OF AG4263 IN RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
PHASE I EVALUATION OF AG4263 IN RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
ANTI-TNF CHIMERIC MONOCLONAL ANTIBODY IN ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
ANTI-TNF CHIMERIC MONOCLONAL ANTIBODY IN ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
EFFECTS OF ANDROGENS ON THE THYMUS$201,938
R01 · FY2000 · DK
ANDROGENS EFFECTS ON B CELL DEVELOPMENT$197,328
R01 · FY2000 · AI
ACTIVATION OF CD28 NEGATIVE T CELLS IN RHEUMATOID ARTHRITIS$592
M01 · FY2000 · RR
BMS 188667 &BMS 224818 INTRAVENOUS FOR RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
ANTI-TNF CHIMERIC MONOCLONAL ANTIBODY IN ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
TYPE 2 COLLAGEN INDUCTION OF RHEUMATOID ARTHRITIS-- OFF NONSTEROIDAL AGENTS$0
M01 · FY2000 · RR
PHASE I EVALUATION OF AG4263 IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR